Prognosis of medullary breast cancer: Analysis of 13 International Breast Cancer Study Group (IBCSG) trials

Annals of Oncology

Volumn 23, Issue 11, 2012, Pages 2843-2851

  Huober, J ^a,b   Gelber, S ^c,d   Goldhirsch, A ^e,f   Coates, A S ^g   Viale, G ^h   ohlschlegel C ^a,b   Price, K N ^d   Gelber, R D ^c,d,i   Regan, M M ^c,i   Thurlimann B ^a,b  

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^b SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^e EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^f Swiss Center for Breast Health   (Switzerland)

^g UNIVERSITY OF SYDNEY   (Australia)

^h UNIVERSITY OF MILAN   (Italy)

ⁱ HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Breast cancer; Histology; Invasive ductal; Medullary; Prognosis

Indexed keywords

EID: 84868116683     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds105     Document Type: Article

References (47)

1. Dendale R, Vincent-Salomon A, Mouret-Fourme E et al. Medullary breast carcinoma: prognostic implications of p53 expression. Int J Biol Markers 2003; 18: 99-105.
2. Reinfuss M, Stelmach A, Mitus J et al. Typical medullary carcinoma of the breast: a clinical and pathological analysis of 52 cases. J Surg Oncol 1995; 60: 89-94.
3. Rakha EA, Putti TC, Abd El-Rehim DM et al. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J Pathol 2006; 208: 495-506.
4. Ridolfi RL, Rosen PP, Port A et al. Medullary carcinoma of the breast: a clinicopathologic study with 10 year follow-up. Cancer 1977; 40: 1365-1385.
5. Pedersen I, Holck S, Mouridsen HT et al. Prognostic comparison of three classifications for medullary carcinoma of the breast. Histopathology 1999; 34: 175-186.
6. Eichhorn JH. Medullary carcinoma, provocative now as then. Semin Diagn Pathol 2004; 21: 65-73.
7. Rosen PP, Lesser ML, Arroyo CD et al. Immunohistochemical detection of HER2/neu in patients with lymph node negative breast cancer. Cancer 1995; 75: 1320-1326.
8. Foschini MP, Eusebi V. Rare (new) entities of the breast and medullary carcinoma. Pathology 2009; 41: 48-56.
9. Bertucci F, Finetti P, Cervera N et al. Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. Cancer Res 2006; 66: 4636-4644.
10. Pertschuk LP, Kim DS, Nayer K et al. Immunocytochemical estrogen and progestin receptor assays in breast cancer with monoclonal antibodies. Cancer 1990; 66: 1663-1670.
11. Jensen ML, Kier H, Melsen F. Medullary breast carcinoma vs. poorly differentiated ductal carcinoma: an immunohistochemical study with keratin 19 and oestrogen receptor staining. Histopathology 1996; 29: 241-245.
12. Orlando L, Renne G, Rocca A et al. Are all high grade breast cancers with no steroid receptor hormone expression alike? The special case of the medullary phenotype. Ann Oncol 2005; 16: 1094-1099.
13. Pedersen L, Zedeler K, Holck S et al. Medullary carcinoma of the breast. Prevalence and prognostic importance of classical risk factors in breast cancer. Eur J Cancer 1995; 31A: 2289-2295.
14. Flucke U, Flucke MT, Hoy L et al. Distinguishing medullary carcinoma of the breast from high-grade hormone receptor-negative invasive ductal carcinoma: an immunohistochemical approach. Histopathology 2010; 56: 852-859.
15. Pedersen L, Zedeler K, Holck S et al. Medullary carcinoma of the breast, proposal for a new simplified histopathological definition. Br J Cancer 1991; 63: 591-595.
16. Pedersen L, Holck S, Schiødt T et al. Medullary carcinoma of the breast, prognostic importance of characteristic histopathological features evaluated in a multivariate Cox analysis. Eur J Cancer 1994; 30A: 1792-1797.
17. Gamel JW, Meyer JS, Feuer E et al. The impact of stage and histology on the long-term clinical course of 163.808 patients with breast carcinoma. Cancer 1996; 77: 1459-1464.
18. Vu-Nishino H, Tavassoli FA, Ahrens WA et al. Clinicopathologic features and long-term outcome of patients with medullary breast carcinoma managed with breast-conserving therapy (BCT). Int J Radiat Oncol Biol Phys 2005; 62: 1040-1047.
19. Vo T, Xing Y, Meric-Bernstam F et al. Long-term outcomes in patients with mucinous, medullary, tubular, and invasive ductal carcinomas after lumpectomy. Am J Surg 2007; 194: 527-531.
20. Fisher ER, Kenny JP, Sass R et al. Medullary cancer of the breast revisited. Breast Cancer Res Treat 1990; 16: 215-229.
21. Cook DL, Weaver DL. Comparison of DNA content, s-phase fraction and survival between medullary and ductal carcinoma of the breast. Am J Clin Pathol 1995; 104: 17-22.
22. Fisher ER, Anderson S, Redmond C et al. Pathologic findings from the National Surgical Adjuvant Breast Project protocol B-06. Cancer 1993; 71: 2507-2514.
23. Vincent-Salomon A, Gruel N, Lucchesi C et al. Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity. Breast Cancer Res 2007; 9: R24.
24. Rakha EA, Aleskandarany M, El-Sayed ME et al. The prognostic significance of inflammation and medullary histological type in invasive carcinoma of the breast. Eur J Cancer 2009; 45: 1780-1787.
25. Rakha EA, El-Sayed E, Green RA et al. Biologic and clinical characteristics of breast cancer with single hormone receptor-positive phenotype. J Clin Oncol 2007; 25: 4772-4778.
26. Ludwig Breast Cancer Study Group. A randomized trial of adjuvant combination chemotherapy with or without prednisone in premenopausal breast cancer patients with metastases in one to three axillary lymph nodes. Cancer Res 1985; 45: 4454-4459.
27. Ludwig Breast Cancer Study Group. Chemotherapy with or without oophorectomy in high-risk premenopausal patients with operable breast cancer. J Clin Oncol 1985; 3: 1059-1067.
28. Pagani O, Price KN, Gelber RD et al. Patterns of recurrence of early breast cancer according to estrogen receptor status: A therapeutic target for a quarter of a century. Breast Cancer Res Treat 2009; 117: 319-324.
29. Colleoni M, Gelber S, Coates A et al. Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer. J Clin Oncol 2001; 19: 4141-4149.
30. Ludwig Breast Cancer Study Group. Combination adjuvant chemotherapy for node-positive breast cancer. Inadequacy of a single perioperative cycle. N Engl J Med 1988; 319: 677-683.
31. The International Breast Cancer Study Group. Duration and reintroduction of adjuvant chemotherapy for node-positive premenopausal breast cancer patients. J Clin Oncol 1996; 14: 1885-1894.
32. The International Breast Cancer Study Group. Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients. J Clin Oncol 1997; 15: 1385-1393.
33. Karlsson P, Sun Z, Braun D et al. Long term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer. Ann Oncol 2011; 22: 2216-2226.
34. Aebi S, Sun Z, Braun D et al. Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: long-term follow up on IBCSG Trial IX. Ann Oncol 2011; 22: 1981-1987.
35. Thürlimann B, Price KN, Gelber RD et al. Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93. Breast Cancer Res Treat 2009; 113: 137-144.
36. International Breast Cancer Study Group. Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93. Ann Oncol 2004; 15: 1749-1759.
37. International Breast Cancer Study Group. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: IBCSG Trial 13-93. J Clin Oncol 2006; 24: 1332-1341.
38. International Breast Cancer Study Group. Effects of a treatment gap during adjuvant chemotherapy in node-positive breast cancer: results of International Breast Cancer Study Group (IBCSG) trials 13-93 and 14-93. Ann Oncol 2007; 18: 1177-1184.
39. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Amer Stat Assoc 1999; 94: 496-509.
40. Saphner T, Tomey T, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 1996; 14: 2738-2746.
41. Weigelt B, Horlings HM, Kreike B et al. Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol 2008; 216: 141-150.
42. Jacquemier J, Padovani L, Rabayrol L et al. Typical medullary breast carcinomas have a basal/myoepithelial phenotype. J Pathol 2005; 207: 260-268.
43. Weigelt B, Geyer FC, Reis-Filho JS. Histological types of breast cancer: how special are they?. Mol Oncol 2010; 4: 192-208.
44. Huober J, Von Minckwitz G, Denkert C et al. Effect of neoadjuvant anthracyclinetaxane based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat 2010; 124: 133-140.
45. Liedtke C, Mazuoni C, Hess KR et al. Response to neoadjuvant chemotherapy and long-term survival in patients with triple negative breast cancer. J Clin Oncol 2008; 26: 1275-1281.
46. National Comprehensive Cancer Network (NCCN). NCCN Guidelines Version 2.2011. Breast Cancer. http://www.nccn.org/professionals/physician_gls/pdf/ breast.pdf (22 December 2011, date last accessed).
47. Goldhirsch A, Wood WC, Coates AS et al. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011; 22: 1736-1747.